Orthocell Expands Canadian Reach with Second Distributor, Sales Expected Soon

Expanding Reach Across Canada

Orthocell Limited (ASX, OCC) has taken a significant step forward in commercialising its flagship nerve repair medical device, Remplir™, by appointing a second distributor in Canada. This Ontario-based distributor will cover eight provinces, complementing the existing distributor who manages Alberta and British Columbia. With this move, Orthocell now boasts full national distribution across the $75 million Canadian nerve repair market.

Strategic Market Positioning

The new distributor brings extensive experience in nerve, spine, and orthopaedic implant sectors, along with established networks that span both urban and rural healthcare providers. This comprehensive coverage is expected to facilitate rapid adoption of Remplir across diverse medical settings. Orthocell’s CEO, Paul Anderson, emphasised the importance of in-country distributors who maintain direct relationships with surgeons and hospitals, describing each appointment as a critical milestone toward generating new revenue streams.

Building Momentum Post-Launch

Following successful launch activities at the prestigious Annual Meeting of the American Society for Surgery of the Hand in Vancouver last October, Orthocell anticipates its first Canadian sales within the current quarter. The company’s US-based marketing and medical education teams will oversee the Canadian rollout, leveraging proven educational programs and scientific data that supported the US launch. This approach aims to maximise efficiency and consistency across North American markets.

Regulatory and Financial Strength

Orthocell secured a Medical Device Licence from Health Canada for Remplir in April 2025, ahead of initial expectations, underscoring regulatory confidence in the product. The company is well-capitalised with over $50 million in cash and no debt, positioning it strongly to accelerate product adoption and deliver a meaningful revenue uplift in fiscal year 2026. Meanwhile, the US rollout continues to gain traction, with ongoing efforts to onboard surgeons and secure hospital approvals across 25 states.

Global Expansion and Future Outlook

Orthocell’s Canadian expansion complements its broader global commercial strategy, which includes recent distributor appointments in Hong Kong and ongoing partnerships in Australia and Singapore. As the company builds momentum across multiple territories, the focus remains on executing targeted sales and marketing initiatives to establish Remplir as a leading solution in peripheral nerve repair.